Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3459-3466. doi: 10.1007/s00405-020-06539-x. Epub 2021 Jan 3.
To evaluate the role of elective neck dissection (END) and of adjuvant radiation (aRT) in polymorphous adenocarcinoma (PAC), previously known as polymorphous low-grade adenocarcinoma (PLGA).
Retrospective cohort study of patients in the National Cancer Database with a histology of PAC (coded as PLGA) at a head and neck site diagnosed between 2004 and 2015. Multivariable Cox proportional hazard modeling was used to assess overall survival in the overall population, and in sub-analyses of clinically N0 disease, positive resection margins, and late stage disease.
A total of 922 patients [66.8% female; mean (SD) age, 60.9 (13.9) years] met inclusion criteria. 74.7% of patients received surgery alone, and 18.0% received surgery and aRT. Only 7.6% of patients with clinically N0 disease received an END, with 10.6% of these having at least one positive node. END did not have a survival benefit compared to no END [HR 1.28 (0.61-2.68)]. Compared to surgery alone, aRT did not have significantly increased survival in the overall population or in late stage [HR 0.68 (0.39-1.19) and HR 0.46 (0.18-1.22), respectively]. On sub-analysis of patients with positive resection margins, aRT had a significant survival benefit compared to surgery alone [HR 0.37 (0.14-0.99)].
PAC is a rare, slow-growing malignant tumor typically treated with surgical excision, with undefined indications for END or aRT. Our findings show END to not have a benefit to overall survival. In patients with positive resection margins, there was a survival benefit for aRT.
评估择期颈清扫术(END)和辅助放疗(aRT)在多形性腺癌(PAC)中的作用,此前这种肿瘤被称为多形性低度恶性腺癌(PLGA)。
回顾性队列研究纳入了 2004 年至 2015 年间在头颈部部位诊断为 PAC(编码为 PLGA)的国家癌症数据库中的患者。采用多变量 Cox 比例风险模型评估总体人群的总生存率,并对临床 N0 疾病、阳性切缘和晚期疾病的亚分析进行评估。
共有 922 名患者[66.8%为女性;平均(SD)年龄 60.9(13.9)岁]符合纳入标准。74.7%的患者仅接受手术治疗,18.0%的患者接受手术和 aRT。仅有 7.6%的临床 N0 疾病患者接受了 END,其中 10.6%的患者至少有一个阳性淋巴结。与未行 END 相比,行 END 并未带来生存获益[风险比(HR)1.28(0.61-2.68)]。与单独手术相比,在总体人群或晚期患者中,aRT 并未显著提高生存率[HR 0.68(0.39-1.19)和 HR 0.46(0.18-1.22)]。在阳性切缘患者的亚分析中,与单独手术相比,aRT 具有显著的生存获益[HR 0.37(0.14-0.99)]。
PAC 是一种罕见的、生长缓慢的恶性肿瘤,通常采用手术切除进行治疗,其 END 和 aRT 的适应证尚未明确。我们的研究结果表明,END 并不能提高总体生存率。对于阳性切缘的患者,aRT 具有生存获益。